ネクセラファーマの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2026/06/08 | 966 | 1,019 | 966 | 983 | -13 | -1.3% | 1,010,900 |
| 2026/06/05 | 977 | 1,005 | 966 | 996 | +62 | +6.6% | 1,344,700 |
| 2026/06/04 | 935 | 956 | 925 | 934 | -19 | -2% | 1,110,800 |
| 2026/06/03 | 990 | 997 | 951 | 953 | -55 | -5.5% | 1,135,500 |
| 2026/06/02 | 1,000 | 1,011 | 967 | 1,008 | -8 | -0.8% | 1,084,800 |
| 2026/06/01 | 1,056 | 1,066 | 1,001 | 1,016 | -51 | -4.8% | 1,115,700 |
| 2026/05/29 | 1,093 | 1,098 | 1,060 | 1,067 | -15 | -1.4% | 817,000 |
| 2026/05/28 | 1,082 | 1,121 | 1,067 | 1,082 | +16 | +1.5% | 968,100 |
| 2026/05/27 | 1,049 | 1,073 | 1,047 | 1,066 | +8 | +0.8% | 627,800 |
| 2026/05/26 | 1,100 | 1,100 | 1,046 | 1,058 | -56 | -5% | 1,445,300 |
| 2026/05/25 | 1,113 | 1,127 | 1,103 | 1,114 | -11 | -1% | 674,800 |
| 2026/05/22 | 1,129 | 1,152 | 1,120 | 1,125 | +3 | +0.3% | 769,500 |
| 2026/05/21 | 1,135 | 1,135 | 1,113 | 1,122 | +14 | +1.3% | 521,200 |
| 2026/05/20 | 1,150 | 1,150 | 1,105 | 1,108 | -33 | -2.9% | 794,800 |
| 2026/05/19 | 1,144 | 1,159 | 1,125 | 1,141 | +21 | +1.9% | 717,500 |
| 2026/05/18 | 1,160 | 1,166 | 1,093 | 1,120 | -52 | -4.4% | 1,261,600 |
| 2026/05/15 | 1,184 | 1,193 | 1,141 | 1,172 | -16 | -1.3% | 1,027,700 |
| 2026/05/14 | 1,177 | 1,212 | 1,176 | 1,188 | +11 | +0.9% | 712,000 |
| 2026/05/13 | 1,192 | 1,204 | 1,167 | 1,177 | -35 | -2.9% | 913,400 |
| 2026/05/12 | 1,238 | 1,245 | 1,202 | 1,212 | -30 | -2.4% | 1,132,600 |
| 2026/05/11 | 1,202 | 1,247 | 1,182 | 1,242 | +75 | +6.4% | 2,442,600 |
| 2026/05/08 | 1,192 | 1,235 | 1,160 | 1,167 | +65 | +5.9% | 4,168,400 |
| 2026/05/07 | 1,100 | 1,102 | 1,078 | 1,102 | +150 | +15.8% | 2,322,800 |
| 2026/05/01 | 967 | 970 | 948 | 952 | -19 | -2% | 842,600 |
| 2026/04/30 | 963 | 988 | 954 | 971 | -2 | -0.2% | 922,300 |
| 2026/04/28 | 973 | 977 | 954 | 973 | +22 | +2.3% | 557,100 |
| 2026/04/27 | 953 | 970 | 937 | 951 | -17 | -1.8% | 552,700 |
| 2026/04/24 | 954 | 972 | 947 | 968 | +13 | +1.4% | 692,100 |
| 2026/04/23 | 999 | 1,008 | 945 | 955 | -53 | -5.3% | 1,634,700 |
| 2026/04/22 | 1,015 | 1,029 | 1,002 | 1,008 | -25 | -2.4% | 886,800 |
| 2026/04/21 | 1,040 | 1,043 | 1,013 | 1,033 | +12 | +1.2% | 763,000 |
| 2026/04/20 | 1,020 | 1,026 | 1,007 | 1,021 | +8 | +0.8% | 428,100 |
| 2026/04/17 | 1,040 | 1,051 | 1,003 | 1,013 | -32 | -3.1% | 1,018,600 |
| 2026/04/16 | 1,034 | 1,085 | 1,032 | 1,045 | ±0 | ±0% | 1,313,000 |
| 2026/04/15 | 1,020 | 1,052 | 1,013 | 1,045 | +34 | +3.4% | 1,035,000 |
| 2026/04/14 | 1,018 | 1,026 | 1,007 | 1,011 | -4 | -0.4% | 586,700 |
| 2026/04/13 | 1,020 | 1,026 | 998 | 1,015 | -6 | -0.6% | 617,500 |
| 2026/04/10 | 1,028 | 1,055 | 1,008 | 1,021 | -3 | -0.3% | 909,400 |
| 2026/04/09 | 1,045 | 1,074 | 1,020 | 1,024 | +9 | +0.9% | 1,230,000 |
| 2026/04/08 | 1,033 | 1,038 | 1,010 | 1,015 | +12 | +1.2% | 717,700 |
| 2026/04/07 | 1,007 | 1,013 | 989 | 1,003 | -12 | -1.2% | 641,200 |
| 2026/04/06 | 1,016 | 1,025 | 1,001 | 1,015 | +10 | +1% | 633,900 |
| 2026/04/03 | 1,025 | 1,033 | 997 | 1,005 | -4 | -0.4% | 770,400 |
| 2026/04/02 | 1,015 | 1,043 | 985 | 1,009 | -6 | -0.6% | 2,458,700 |
| 2026/04/01 | 992 | 1,022 | 960 | 1,015 | +143 | +16.4% | 6,730,900 |
| 2026/03/31 | 863 | 888 | 855 | 872 | +5 | +0.6% | 646,900 |
| 2026/03/30 | 860 | 869 | 850 | 867 | -38 | -4.2% | 653,300 |
| 2026/03/27 | 885 | 917 | 881 | 905 | +35 | +4% | 789,100 |
| 2026/03/26 | 888 | 888 | 857 | 870 | -9 | -1% | 420,900 |
| 2026/03/25 | 872 | 889 | 864 | 879 | +36 | +4.3% | 598,600 |
1~
50
件表示中 / 5348件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ネクセラファーマ | 97,700円 | +39.5% | - | 0.00% | 16.45倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| サンバイオ | 123,900円 | - | - | 0.00% | - | 7.25倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
| 栄研化 | 278,400円 | +0.2% | +2.0% | 2.08% | 44.34倍 | 2.09倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
| オンコリス | 285,000円 | +4185.7% | - | 0.00% | - | 20.91倍 |
|
腫瘍溶解ウイルス食道がん治療薬「テロメライシン」開発が柱。導出神経難病薬は米国治験中 |
| あすかHD | 256,400円 | +2.6% | +7.7% | 2.54% | 15.16倍 | 1.03倍 |
|
武田と親密。婦人科領域に強い。先発品比率引き上げに注力。21年春にあすか製薬が持株会社化 |
市場注目の銘柄
チャート関連のコラム